金斯瑞生物科技(01548.HK):傳奇生物擬公開發售750萬股美國存托股份 預計獲得所得款3億美元
格隆匯12月19日丨金斯瑞生物科技(01548.HK)公佈,2021年12月16日,傳奇生物科技股份有限公司與Morgan Stanley & Co.LLC、J.P.Morgan Securities LLC、Jefferies LLC、Piper Sandler & Co.及Barclays Capital Inc.訂立承銷協議,內容有關向公眾承銷公開發售750萬股美國存托股份,代表1500萬股普通股,價格為每股美國存托股份40美元。傳奇生物預計從發售中獲得所得款項總額3億美元(扣除承銷折扣、佣金及預計發售費用前)。
發售預期於2021年12月20日或前後完成,惟須待慣常的完成條件達成。傳奇生物亦已向承銷商授予30日選擇權,可按公開發售價(減去承銷折扣及佣金)購買最多額外112.5萬股美國存托股份。
發售乃根據於2021年7月1日提交併自動生效的F-3表格(文件編號333-257609)中傳奇生物有效上架註冊聲明(經日期為2021年12月16日的補充招股章程補充)進行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.